• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis - Product Image

Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis

  • Published: November 2012
  • 36 pages
  • GlobalData

Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Influvac is a trivalent, inactivated READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile - Influvac
5.3.1 Overview
6 Appendix
6.1 Bibliography
6.2 Abbreviations
6.3 Methodology
6.4 Forecasting Methodology
6.4.1 Vaccine Coverage
6.4.2 Influenza Vaccine Tender System Assumptions
6.4.3 General Pricing Assumptions
6.4.4 Individual Vaccine Assumptions
6.5 Physicians and Specialists Included in this Study
6.6 Primary Research - Prescriber Survey
6.7 About the Authors
6.7.1 Authors
6.7.2 Global Head of Healthcare
6.8 About Us
6.9 Contact Us
6.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Product Profile - Influvac
Table 7: Influvac SWOT Analysis, 2012
Table 8: Global Sales Forecasts ($m) for Influvac, 2012-2022
Table 9: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
Table 10: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos